STOCK TITAN

Seelos Therapeutics Inc - SEEL STOCK NEWS

Welcome to our dedicated news page for Seelos Therapeutics (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on Seelos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seelos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seelos Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.8%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
Seelos Therapeutics Inc

Nasdaq:SEEL

SEEL Rankings

SEEL Stock Data

6.32M
13.40M
2%
21.66%
5.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About SEEL

seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a